CY1115337T1 - Παραγωγα ν-οξειδιου και/ή di-n- οξειδιου των σταθεροποιητων/παραγοντων τροποποιησης ληπτη ντοπαμινης (dopamine) που εμφανιζουν βελτιωμενα προφιλ καρδιαγγειακων παρενεργειων - Google Patents
Παραγωγα ν-οξειδιου και/ή di-n- οξειδιου των σταθεροποιητων/παραγοντων τροποποιησης ληπτη ντοπαμινης (dopamine) που εμφανιζουν βελτιωμενα προφιλ καρδιαγγειακων παρενεργειωνInfo
- Publication number
- CY1115337T1 CY1115337T1 CY20141100304T CY141100304T CY1115337T1 CY 1115337 T1 CY1115337 T1 CY 1115337T1 CY 20141100304 T CY20141100304 T CY 20141100304T CY 141100304 T CY141100304 T CY 141100304T CY 1115337 T1 CY1115337 T1 CY 1115337T1
- Authority
- CY
- Cyprus
- Prior art keywords
- oxide
- dopamine
- disorders
- velgerenglier
- producers
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title abstract 4
- 229960003638 dopamine Drugs 0.000 title abstract 2
- 102000015554 Dopamine receptor Human genes 0.000 title 1
- 108050004812 Dopamine receptor Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0700893 | 2007-04-12 | ||
| EP20080741904 EP2146961B1 (en) | 2007-04-12 | 2008-04-11 | N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115337T1 true CY1115337T1 (el) | 2017-01-04 |
Family
ID=39864178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100304T CY1115337T1 (el) | 2007-04-12 | 2014-04-25 | Παραγωγα ν-οξειδιου και/ή di-n- οξειδιου των σταθεροποιητων/παραγοντων τροποποιησης ληπτη ντοπαμινης (dopamine) που εμφανιζουν βελτιωμενα προφιλ καρδιαγγειακων παρενεργειων |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9139525B2 (enExample) |
| EP (1) | EP2146961B1 (enExample) |
| JP (1) | JP5393654B2 (enExample) |
| CN (1) | CN101711236B (enExample) |
| AU (1) | AU2008239841B2 (enExample) |
| BR (1) | BRPI0810161A2 (enExample) |
| CA (1) | CA2683719C (enExample) |
| CY (1) | CY1115337T1 (enExample) |
| DK (1) | DK2146961T3 (enExample) |
| ES (1) | ES2458592T3 (enExample) |
| HR (1) | HRP20140380T1 (enExample) |
| IL (1) | IL201401A (enExample) |
| MX (1) | MX2009011020A (enExample) |
| NZ (1) | NZ580856A (enExample) |
| PL (1) | PL2146961T3 (enExample) |
| PT (1) | PT2146961E (enExample) |
| RU (1) | RU2470013C2 (enExample) |
| SI (1) | SI2146961T1 (enExample) |
| WO (1) | WO2008127188A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| WO2010058019A1 (en) * | 2008-11-24 | 2010-05-27 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission |
| WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US9018202B2 (en) * | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
| MX343620B (es) | 2011-09-07 | 2016-11-11 | Teva Pharmaceuticals Int Gmbh | Forma polimorfica de clorhidrato de pridopidina. |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| TW201613859A (en) * | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| EP3419622B1 (en) | 2016-02-24 | 2024-03-06 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| ES2972205T3 (es) | 2017-01-20 | 2024-06-11 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento del síndrome x frágil |
| HUE061505T2 (hu) | 2017-08-14 | 2023-07-28 | Prilenia Neurotherapeutics Ltd | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel |
| JP2020532517A (ja) | 2017-08-30 | 2020-11-12 | プリレニア ニューロセラピューティクス リミテッド | 高濃度プリドピジン製剤 |
| CA3075020C (en) | 2017-09-08 | 2021-12-07 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
| AU2020243692B2 (en) | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1217296A (en) | 1917-01-11 | 1917-02-27 | Lewis A Peckham | Shock-absorber. |
| US2813098A (en) | 1955-08-16 | 1957-11-12 | Upjohn Co | 3-methoxy-n-methylmorphinan n-oxide |
| US2813097A (en) | 1955-08-16 | 1957-11-12 | Upjohn Co | 3-hydroxy-n-methylmorphinan-n-oxide |
| US3131185A (en) | 1959-03-18 | 1964-04-28 | Orsymonde | Nicotinic esters of hydroxyl derivatives of the phenanthrenic alkaloids of opium, and process for the preparation of these esters |
| BE638369A (enExample) | 1962-10-10 | |||
| CH481124A (de) | 1966-09-21 | 1969-11-15 | Geigy Ag J R | Verfahren zur Herstellung von neuen, kondensierten heterocyclischen Verbindungen |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| DK0641320T3 (da) * | 1991-04-17 | 2001-08-20 | Upjohn Co | Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister |
| AU676993B2 (en) | 1991-06-27 | 1997-04-10 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| IL112099A (en) * | 1993-12-23 | 1999-07-14 | Ortho Pharma Corp | N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them |
| CA2144669A1 (en) | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
| US6121259A (en) * | 1998-11-23 | 2000-09-19 | Sepracor Inc. | Olanzapine-N-oxide compositions and methods |
| SE9904723D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE0200301D0 (sv) * | 2002-02-01 | 2002-02-01 | Axon Biochemicals Bv | Thio-carbostyril derivative |
| MXPA06013941A (es) * | 2004-06-08 | 2007-12-10 | Neurosearch Sweden Ab | Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina. |
| CA2569843A1 (en) | 2004-06-08 | 2005-12-22 | A. Carlsson Research Ab | New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
| WO2006020573A2 (en) * | 2004-08-11 | 2006-02-23 | Barbeau Donald L | Noncardiotoxic pharmaceutical compounds |
| ES2659577T3 (es) * | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| JP2009504799A (ja) * | 2005-08-22 | 2009-02-05 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | ピペラジンおよびピペリジン誘導体のプロドラッグとしてのｎ−オキシド |
| SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| UA96756C2 (en) * | 2006-05-02 | 2011-12-12 | Эббот Хелскеа Продактс Б.В. | N-oxides of pyridylmethylpiperazine and -piperidine derivatives |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| US20130203886A1 (en) * | 2010-03-05 | 2013-08-08 | Nileshkumar Prakash Kukalyekar | Process for the production of an uhmwpe article |
| NZ608120A (en) * | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| MX343620B (es) | 2011-09-07 | 2016-11-11 | Teva Pharmaceuticals Int Gmbh | Forma polimorfica de clorhidrato de pridopidina. |
| EP2787997A4 (en) * | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| BR112014024672A8 (pt) * | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| MX2015003812A (es) * | 2012-09-27 | 2015-07-17 | Teva Pharma | Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington. |
| US20150209346A1 (en) * | 2012-09-27 | 2015-07-30 | Teva Pharmaceutical Industries, Ltd. | Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
-
2008
- 2008-04-11 MX MX2009011020A patent/MX2009011020A/es unknown
- 2008-04-11 CN CN2008800175988A patent/CN101711236B/zh not_active Expired - Fee Related
- 2008-04-11 BR BRPI0810161 patent/BRPI0810161A2/pt not_active IP Right Cessation
- 2008-04-11 SI SI200831188T patent/SI2146961T1/sl unknown
- 2008-04-11 HR HRP20140380AT patent/HRP20140380T1/hr unknown
- 2008-04-11 RU RU2009141300/04A patent/RU2470013C2/ru not_active IP Right Cessation
- 2008-04-11 AU AU2008239841A patent/AU2008239841B2/en not_active Ceased
- 2008-04-11 PL PL08741904T patent/PL2146961T3/pl unknown
- 2008-04-11 ES ES08741904T patent/ES2458592T3/es active Active
- 2008-04-11 CA CA2683719A patent/CA2683719C/en not_active Expired - Fee Related
- 2008-04-11 US US12/595,472 patent/US9139525B2/en active Active
- 2008-04-11 PT PT08741904T patent/PT2146961E/pt unknown
- 2008-04-11 DK DK08741904T patent/DK2146961T3/da active
- 2008-04-11 EP EP20080741904 patent/EP2146961B1/en not_active Not-in-force
- 2008-04-11 JP JP2010502976A patent/JP5393654B2/ja not_active Expired - Fee Related
- 2008-04-11 NZ NZ580856A patent/NZ580856A/en unknown
- 2008-04-11 WO PCT/SE2008/050414 patent/WO2008127188A1/en not_active Ceased
-
2009
- 2009-10-11 IL IL201401A patent/IL201401A/en not_active IP Right Cessation
-
2014
- 2014-04-25 CY CY20141100304T patent/CY1115337T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2683719C (en) | 2015-07-14 |
| ES2458592T3 (es) | 2014-05-06 |
| PT2146961E (pt) | 2014-04-30 |
| IL201401A0 (en) | 2010-05-31 |
| EP2146961A1 (en) | 2010-01-27 |
| JP5393654B2 (ja) | 2014-01-22 |
| NZ580856A (en) | 2011-11-25 |
| RU2470013C2 (ru) | 2012-12-20 |
| BRPI0810161A2 (pt) | 2014-12-30 |
| SI2146961T1 (sl) | 2014-08-29 |
| US9139525B2 (en) | 2015-09-22 |
| EP2146961B1 (en) | 2014-01-29 |
| AU2008239841A1 (en) | 2008-10-23 |
| CN101711236A (zh) | 2010-05-19 |
| PL2146961T3 (pl) | 2014-09-30 |
| MX2009011020A (es) | 2009-10-30 |
| US20100105736A1 (en) | 2010-04-29 |
| RU2009141300A (ru) | 2011-05-20 |
| DK2146961T3 (da) | 2014-04-28 |
| WO2008127188A1 (en) | 2008-10-23 |
| IL201401A (en) | 2015-10-29 |
| JP2010523651A (ja) | 2010-07-15 |
| EP2146961A4 (en) | 2011-08-03 |
| HRP20140380T1 (hr) | 2014-08-15 |
| AU2008239841B2 (en) | 2013-07-18 |
| CN101711236B (zh) | 2012-10-31 |
| CA2683719A1 (en) | 2008-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009011020A (es) | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. | |
| CY1117045T1 (el) | Ενωσεις κινουκλιδινης ως προσδετες του νικοτινικου υποδοχεα ακετυλχολινης αλφα-7 | |
| CY1118452T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης | |
| CY1111206T1 (el) | Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων | |
| CY1120054T1 (el) | Ετεροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νευρολογικων και ψυχολογικων διαταραχων | |
| CY1120881T1 (el) | Ανταγωνιστες υποδοχεα 5-ητ3 | |
| CY1118061T1 (el) | Δικυκλικα παραγωγα heterocyclyl σαν καταστολεις κινασης (kinase) fgfr για θεραπευτικη χρηση | |
| CY1120073T1 (el) | Παραγωγα πυραζολο-αμινοπυριμιδινης ως ρυθμιστες της lrrk2 | |
| GEAP202014908A (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| CY1111603T1 (el) | Παραγωγα benzimidazole και η χρηση τους για την τροποποιηση της συνθεσης ληπτη gabaa | |
| CY1114400T1 (el) | Θεραπευτικες εφαρμογες των παραγωγων κιναζολινεδιονης | |
| CY1110115T1 (el) | Παραγωγα ακετυλενυλο-πυραζολο-πυριμιδινης ως mglur2 ανταγωνιστες | |
| CY1111702T1 (el) | Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1 | |
| DE602005009745D1 (de) | Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür | |
| CO6382123A2 (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
| TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
| CY1113178T1 (el) | Σταθεροποιημενες αμορφες μορφες της μεσυλικης ιματινιβης | |
| BRPI0511907A8 (pt) | novos derivados de fenilpiperidinas/piperazinas dissubstituídos como moduladores da neurotransmissão de dopamina | |
| BR112014031360A2 (pt) | derivado de metil amina cíclica heteroaromática | |
| PA8795601A1 (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3 | |
| CY1119800T1 (el) | Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων | |
| BR112014001908A2 (pt) | derivados aza heterocíclicos substituídos | |
| AR066701A1 (es) | 3-( imidazolil)- pirazolo {3,4-b] piridinas, composicion farmaceutica, proceso y uso en terapia | |
| ATE537143T1 (de) | Spiro(5.5)undecan derivate | |
| CY1117855T1 (el) | Διαδικασια για τη συνθεση των παραγωγων 3,6-διυδρο-1,3,5-τριαζινης |